##  [Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies](/us-en/news/media-releases/novartis-ain457-secukinumab-showed-significant-symptom-improvement-two-pivotal-phase-iii-ankylosing-spondylitis-studies-0 "Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies") 

  Nov 15, 2014